viewIronRidge Resources Ltd

Ewoyaa Stands out From the Lithium Crowd

IronRidge Resources (LON:IRR) has completed its scoping study on the Ewoyaa Lithium Project, located in Ghana. This study returned robust economics with a post-tax net present value using an 8% discount rate (NPV8) of US$345mln and a post-tax internal rate of return (IRR) of 125%, assuming a conservative spodumene concentrate price of US$650 per tonne (t). Compared to its peer group developing spodumene concentrate operations, Ewoyaa is a high-volume project with low capital expenditure (capex) intensity and a low operating expenditure (opex) requirement.

Over the eight-year mine life, the project is expected to generate US$1.55bn of revenue with underlying earnings (EBITDA) of US$854mln. The operation will be a conventional operation with a series of seven proximal open pits (Figure 1) with simple processing flow sheet using dense media separation.

Figure 1 - Proposed Open Pits
Source: IronRidge Resources

The economics could be further improved with the sale of a feldspar bi-product, and by extending the life-of-mine using material from the historic Egyasimanku Hill deposit (1.5mln tonnes at a grade of 1.66% Li2O) and other regional targets that have recently been identified. Additional drilling is underway at these regional targets and is already returning intersections of spodumene-bearing pegmatite.


Quick facts: IronRidge Resources Ltd


Price: 20.1 GBX

Market Cap: £115.32 m

What's in the report?

Financial results and forecasts
Growth drivers
Market conditions
Milestones & inflection points


Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...


Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

FTSE 100 starts the shortened trading week flat

FTSE 100 was going nowhere at the start of trading even though US markets hit new record highs overnight. London’s blue-chip index was almost unchanged at 7,148 in early dealings. GlaxoSmithKline has started phase III trials of a Covid-19 vaccine that will test itself against rival...

3 weeks, 2 days ago

13 min read